Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Naglazyme approved in Japan

BioMarin Pharmaceutical Inc. has announced that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has received approval for its Marketing Application for Naglazyme(R) (galsulfase) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with Mucopolysaccharidosis VI ( MPS VI).

1 Apr 2008

Ebola virus vaccines for humans

One of the world's deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to adapt them for human use.

31 Mar 2008

Environmental factors linked to development of autoimmune diseases

Scientists working at the MRC National Institute for Medical Research have shown that environmental factors can influence the development of autoimmune diseases like multiple sclerosis.

28 Mar 2008

Wistar Institute shares cell lines

Cell lines developed by scientists at The Wistar Institute in Philadelphia have recently been made available to researchers around the globe through the catalog collection at the Coriell Institute for Medical Research of Camden, N.J.

26 Mar 2008

New method for rapid screening large numbers of antigens

A team of Washington State University scientists has devised a method that could lead to the development of vaccines against some of the most troubling infectious diseases we face diseases that have so far been difficult or impossible to vaccinate against.

26 Mar 2008

PharmAthene signs agreement to acquire biodefense vaccines business from Avecia

PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against biological and chemical threats, and Avecia Biologics Limited, a contract manufacturer of biopharmaceuticals, has announced that the companies have entered into a definitive sale and purchase agreement under which PharmAthene will acquire all of the assets and intellectual property related to Avecia's biodefense vaccines business.

24 Mar 2008

What change does prokineticin 2/Bv8 have in human hepatocellular carcinoma?

Liver hepatocarcinoma is a highly vascularized cancer, and more and more research is focused on the molecules controlling angiogenesis.

19 Mar 2008

MedImmune advances clinical development of antibody targeting interleukin-9 in patients with asthma

MedImmune has announced that its clinical program studying an investigational treatment targeting interleukin-9 (IL-9) has advanced with the start of a new trial in patients with asthma.

19 Mar 2008

New understanding of rare immune disorder called Job's syndrome

Scientists have made another major breakthrough--the second in the past year--in understanding a rare immune disorder called Job's syndrome.

18 Mar 2008

An anti-inflammatory response to the vegan diet

Rheumatoid arthritis (RA) patients who eat a gluten-free vegan diet could be better protected against heart attacks and stroke.

18 Mar 2008

New diagnostic test for cancer promises less trauma for patients

A rapid new diagnostic test developed by Sydney researchers will mean fewer tests and less trauma for cancer patients says Richard Christopherson, who has a Personal Chair in the School of Molecular and Microbial Biosciences in the Faculty of Science.

17 Mar 2008

Modified virus vaccine shows promise in mouse model of breast cancer

Researchers have shown that vaccinating mice with a modified form of a virus containing proteins from breast cancer cells can kill large breast cancer tumors and tumors that have spread to the lungs.

17 Mar 2008

Cancer drug allergies

Cancer patients from the Southeastern United States who are treated with the drug cetuximab, known commercially as Erbitux, are far more likely to suffer severe allergic reactions than patients in other regions of the country.

14 Mar 2008

Researchers find benefit for lymphoma patients in combined PET-CT scanning

Combined positron emission tomography (PET) and computed tomography (CT) imaging of lymphoma patients is a more effective method to evaluate response to radiation therapy, and may help patients avoid unnecessary follow-up treatments, a study by researchers at the University of Southern California (USC) suggests.

13 Mar 2008

Researchers find cause of severe allergic reaction to cetuximab

Clinicians have been perplexed by the fact that some patients given the drug cetuximab - an immune-based therapy commonly used to treat persons diagnosed with head and neck cancer, or colon cancer - have a severe and rapid adverse reaction to the drug.

13 Mar 2008

Home test kit confirms men's post-vasectomy sterility

Technology developed at the University of Virginia could soon have a dramatic impact on male contraception practices throughout the U.S. Earlier this year, the U.S. Food and Drug Administration approved SpermCheck Vasectomy, a home test that confirms men's post-vasectomy sterility and is based on discoveries made at U.Va.

12 Mar 2008

Turning off rogue macrophages

University of Pennsylvania scientists studying macrophages, the biological cells that spring from white blood cells to eat and destroy foreign or dying cells, have discovered how these "policemen" differentiate between friend and foe.

12 Mar 2008

Switch for programmed cell death promotes spread of glioblastoma

Malignant tumors have usually lost their ability to destroy themselves by programmed cell death, or apoptosis.

12 Mar 2008

Cervarix shows long-term protection from cervical cancer

New data demonstrate that GlaxoSmithKline's cervical cancer candidate vaccine, CERVARIX provides significant protection for women against the four most common cancer- causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to date.

12 Mar 2008

Anadis licenses antibody technologies from ImmuCell

Anadis Limited, an Australian-based biotechnology company focused on milk derived polyclonal antibodies and other milk-derived bioactives, announced today that it had signed a final agreement with ImmuCell Corporation, a biotechnology company headquartered in Portland, Maine, USA.

11 Mar 2008